CuraSen Therapeutics

CuraSen’s mission and passion is to create innovative drugs to improve the quality of life for people with CNS and neurodegenerative diseases.

[CuraSen Therapeutics @curaseninc]

Dr. Gabriel Vargas will present positive P2a data with our combination adrenergic activator, CST-2032/CST-107, in Alzheimer’s and Parkinson’s patients 3/9/24 at 17:25 UTC at AD/PD, showing improvements across several cognitive domains. #AD#PD#MCI
https://t.co/XgnyWazAPX

[CuraSen Therapeutics @curaseninc]

Sending warm wishes for a joyful holiday season from the Curasen team. We look forward to advancing clinical testing of our novel therapeutics for the treatment of Alzheimer’s and Parkinson’s diseases, and other neurodegenerative diseases, in 2024. #Alzheimer's #Parkinson's

[CuraSen Therapeutics @curaseninc]

Dr. John Harrison will be presenting encouraging Phase 2 data in Alzheimer's at CTAD this week from our late-breaking abstract (#PO34) “Combination Treatment of a Novel β2-Adrenoceptor Agonist, CST-2032, and Nadolol Improves Cognitive Measures in Patients with Alzheimer’s"

[CuraSen Therapeutics @curaseninc]

We’re thrilled to receive a $5.8M investment from the Alzheimer’s Drug Discovery Fund to advance CST-3056, an α1A-AR agonist. Alpha-1A adrenoceptors help regulate neurotransmission, making them an attractive target for drug development in Alzheimer's. https://t.co/XgnyWazAPX

[CuraSen Therapeutics @curaseninc]

CuraSen will be presenting additional Phase 2 data in Parkinson’s disease at the ECNP Congress in Barcelona on 10/8/23. CST-103/CST-107 has been shown to improve cognition/memory and markers of emotional resilience in PD patients. https://t.co/XUIWLUXzuW

[CuraSen Therapeutics @curaseninc]

Our Phase 2 data with novel drug combination, CST-103/CST-107, showed rapid-onset cognition and mood benefit in Parkinson’s patients. We look forward to presenting these results and encouraging Phase 1 data from our 2nd neuro program this Sat at AD/PD'23. https://t.co/kAEm6WC4OC

[CuraSen Therapeutics @curaseninc]

We are pleased to announce positive top-line Phase 2 data in patients with Parkinson's disease or mild cognitive impairment with CST-103/CST-107 combination treatment. #Parkinsonsdisease #MCI https://t.co/E32uebF5K4

[CuraSen Therapeutics @curaseninc]

CuraSen Therapeutics has treated its first patients in a Phase 2a study with CST-2032 in mild dementia or cognitive impairment due to Alzheimer's or Parkinson's disease #dementia #MCI #Alzheimer's #Parkinsons #Phase2 https://t.co/07dGuGZU6i

[CuraSen Therapeutics @curaseninc]

We are pleased to present Phase 1B data today with CST-103 demonstrating significant increases in cerebral blood flow in patients with mild cognitive impairment (MCI) or Parkinson's disease at the CTAD conference. https://t.co/vdvBd5j3bA #CTAD #MCI #Parkinson's

[CuraSen Therapeutics @curaseninc]

https://t.co/wLQPrffskw

[CuraSen Therapeutics @curaseninc]

CuraSen Launches with $54.5 Million Series A Financing with Industry Veterans at Helm https://t.co/j9rno0jo4j

[CuraSen Therapeutics @curaseninc]

Check out New webpage. https://t.co/i9hxcoFxkN

[Alzheimer's Association, Northern California @AlzNorCalNorNev]

Great idea #4 to #ENDALZ. Robert Booth of CuraSen will modify promising drug candidates and enable them to access the CNS. #AIA

[CuraSen Therapeutics @curaseninc]

CuraSen will present its Drug Discovery progress in Alzheimer’s Innovation Award meeting on September 18 2017 #AIA